US pharmaceutical rare blood
disease specialist company Alexion
has announced second quarter
2014 results highlighting sales
increase of Soliris (eculizumab) of
38% to $US512.5m and net income
increase of 74% to US$166.5m,
equivalent to US$0.83 per share,
compared with Q2 2013 income of
US$95.9m, US$0.73 per share.
CLICK HERE for the full report.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.